(Stroke. 2000;31:26.)
© 2000 American Heart Association, Inc.
Original Contributions |
Tissue Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex as Risk Factors for the Development of a First Stroke
From the Department of Medicine, Skellefteå County Hospital (L.J., J-H.J., K.B.), and Departments of Clinical Chemistry (T.K.N.), Public Health and Clinical Medicine (B.S., G.H.), and the Medical Bank (G.H.), Umeå University Hospital (Sweden).
Correspondence to Lars Johansson, Department of Medicine, Skellefteå County Hospital, Skellefteå, S-931 86 Sweden. E-mail lars.johansson.ss{at}vll.se
Background and Purpose—Abnormalities in the fibrinolytic system have been associated with an increased risk for stroke in a few studies. This study was designed to test whether plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and tPA/PAI-1 complex could predict a first-ever stroke.
Methods—The study was an incident case-control study nested within the Västerbotten Intervention Program and the Northern Sweden Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) cohorts. In this study 108 first-ever stroke cases were defined according to the MONICA classification, and 216 controls from the same cohort were randomly selected and matched for age, sex, sampling time, and geographic region.
Results—Stroke occurred on average 30 months after the blood sampling date. The mean plasma concentration of tPA/PAI-1 complex was higher for the stroke cases than for the controls (3.9 versus 3.0 µg/L). In univariate regression analysis, significantly higher odds ratios were found for the tPA/PAI-1 complex as continuous variable. When divided into quartiles, the odds ratio was 2.74 for the highest quartile compared with the lowest. In the multivariate model, the tPA/PAI-1 complex remained an independent predictor for stroke. Additionally, tPA mass concentration quartiles 3 and 4 showed a significant association with all stroke as outcome. No association was found, however, for PAI-1. In subgroup analysis of cerebral hemorrhage (n=18), the mean tPA/PAI-1 complex level was higher for the cases than for the controls (4.8 versus 3.0 µg/L), and in multivariate analysis including all controls (n=216), only tPA/PAI-1 complex remained significant.
Conclusions—This prospective study shows that tPA/PAI-1 complex, a novel fibrinolytic marker, is independently associated with the development of a first-ever stroke, especially hemorrhagic stroke. This finding supports the hypothesis that disturbances in fibrinolysis precede a cerebrovascular event.
Key Words: cerebral hemorrhage • cerebral infarction • fibrinolysis • risk factors
This article has been cited by other articles:
 |
|
 |
|
  A. A. Komissarov, A. Zhou, and P. J. Declerck Modulation of Serpin Reaction through Stabilization of Transient Intermediate by Ligands Bound to {alpha}-Helix F J. Biol. Chem., September 7, 2007; 282(36): 26306 - 26315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Kovacs and J. Yamamoto Spontaneous Thrombolysis: A Forgotten Determinant of Life or Death Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 358 - 363. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Jood, P. Ladenvall, A. Tjarnlund-Wolf, C. Ladenvall, M. Andersson, S. Nilsson, C. Blomstrand, and C. Jern Fibrinolytic Gene Polymorphism and Ischemic Stroke Stroke, October 1, 2005; 36(10): 2077 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Wannamethee, G. D.O. Lowe, A. G. Shaper, A. Rumley, L. Lennon, and P. H. Whincup Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease Eur. Heart J., September 1, 2005; 26(17): 1765 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-G. Wiklund, L. Nilsson, S. N. Ardnor, P. Eriksson, L. Johansson, B. Stegmayr, A. Hamsten, D. Holmberg, and K. Asplund Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Risk of Stroke: Replicated Findings in Two Nested Case-Control Studies Based on Independent Cohorts Stroke, August 1, 2005; 36(8): 1661 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Rikitake and J. K. Liao Rho-Kinase Mediates Hyperglycemia-Induced Plasminogen Activator Inhibitor-1 Expression in Vascular Endothelial Cells Circulation, June 21, 2005; 111(24): 3261 - 3268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-G. V. Giardina, H. J. Chen, R. R. Sciacca, and L. E. Rabbani Dynamic Variability of Hemostatic and Fibrinolytic Factors in Young Women J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6179 - 6184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jannes, M. A. Hamilton-Bruce, L. Pilotto, B. J. Smith, C. G. Mullighan, P. G. Bardy, and S. A. Koblar Tissue Plasminogen Activator -7351C/T Enhancer Polymorphism Is a Risk Factor for Lacunar Stroke Stroke, May 1, 2004; 35(5): 1090 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Johansson, J.-H. Jansson, B. Stegmayr, T. K. Nilsson, G. Hallmans, and K. Boman Hemostatic Factors as Risk Markers for Intracerebral Hemorrhage: A Prospective Incident Case-Referent Study Stroke, April 1, 2004; 35(4): 826 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hoekstra, J. M. Geleijnse, C. Kluft, E. J. Giltay, F. J. Kok, and E. G. Schouten 4G/4G Genotype of PAI-1 Gene Is Associated With Reduced Risk of Stroke in Elderly Stroke, December 1, 2003; 34(12): 2822 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roest and J. D. Banga Editorial Comment-- Genetic Make-Up for Increased PAI-1 Expression Protects Against Stroke Stroke, December 1, 2003; 34(12): 2828 - 2829. [Full Text] [PDF]
|
|
|
|
|
|
H. Austin, M. I. Chimowitz, H. A. Hill, S. Chaturvedi, L. R. Wechsler, R. J. Wityk, E. Walz, J. L. Wilterdink, B. Coull, C. A. Sila, et al. Cryptogenic Stroke in Relation to Genetic Variation in Clotting Factors and Other Genetic Polymorphisms Among Young Men and Women * Editorial Comment Stroke, December 1, 2002; 33(12): 2762 - 2768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hadigan, J. Rabe, and S. Grinspoon Sustained Benefits of Metformin Therapy on Markers of Cardiovascular Risk in Human Immunodeficiency Virus-Infected Patients with Fat Redistribution and Insulin Resistance J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4611 - 4615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Folsom, N. Aleksic, E. Park, V. Salomaa, H. Juneja, and K. K. Wu Prospective Study of Fibrinolytic Factors and Incident Coronary Heart Disease : The Atherosclerosis Risk in Communities (ARIC) Study Arterioscler. Thromb. Vasc. Biol., April 1, 2001; 21(4): 611 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Insulin Resistance in HIV Lipodystrophy Syndrome AIDS Clinical Care, February 1, 2001; 2001(201): 7 - 7. [Full Text]
|
|
|
|
|
|
A. Elbaz, F. Cambien, P. Amarenco, M. Roest, Y. T. van der Schouw, D. E. Grobbee, M. J. Tempelman, P. G. de Groot, J. J. Sixma, and J. D. Banga Plasminogen Activator Inhibitor Genotype and Brain Infarction Response Circulation, January 16, 2001; 103 (2): e13 - e14. [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Tegos, E. Kalodiki, S.-S. Daskalopoulou, and A. N. Nicolaides Stroke: Epidemiology, Clinical Picture, and Risk Factors: Part I of III Angiology, October 1, 2000; 51(10): 793 - 808. [Abstract] [PDF]
|
|